Compare NTWK & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTWK | TIL |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | 1460 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.7M | 54.8M |
| IPO Year | 1997 | 2021 |
| Metric | NTWK | TIL |
|---|---|---|
| Price | $4.52 | $7.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | ★ 33.5K | 22.2K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.67 | 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $73,088,687.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.40 | N/A |
| 52 Week Low | $2.73 | $5.67 |
| 52 Week High | $5.75 | $34.85 |
| Indicator | NTWK | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 62.54 | 39.66 |
| Support Level | $4.55 | $7.59 |
| Resistance Level | $4.86 | $8.30 |
| Average True Range (ATR) | 0.26 | 0.17 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 67.72 | 10.87 |
NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.